Moleculin Biotech Files 8-K on Shareholder Votes
Ticker: MBRX · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1659617
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
TL;DR
Moleculin Biotech filed an 8-K on Aug 18, 2025, regarding shareholder votes. Check for details on corporate actions.
AI Summary
Moleculin Biotech, Inc. filed an 8-K on August 18, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31).
Why It Matters
This filing informs investors about important corporate actions and decisions that have been put to a vote by Moleculin Biotech's shareholders.
Risk Assessment
Risk Level: low — This is a routine filing reporting on shareholder votes, not indicating immediate financial distress or significant operational changes.
Key Numbers
- 001-37758 — SEC File Number (Identifies the company's filing history with the SEC.)
- 47-4671997 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- August 18, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 713-300-5160 (phone_number) — Registrant's telephone number
FAQ
What specific matters were submitted to a vote of Moleculin Biotech's security holders?
The filing indicates that matters were submitted to a vote, but the specific details of these matters are not provided in the excerpt.
When was the earliest event reported in this Form 8-K?
The earliest event reported in this Form 8-K was on August 18, 2025.
What is Moleculin Biotech, Inc.'s principal executive office address?
The principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Moleculin Biotech's fiscal year end?
Moleculin Biotech's fiscal year ends on December 31.
Filing Stats: 1,205 words · 5 min read · ~4 pages · Grade level 12.8 · Accepted 2025-08-18 16:00:48
Filing Documents
- mbrx20250818c_8k.htm (8-K) — 54KB
- mbrx20250818c_8kimg001.jpg (GRAPHIC) — 5KB
- 0001437749-25-027241.txt ( ) — 200KB
- mbrx-20250818.xsd (EX-101.SCH) — 3KB
- mbrx-20250818_def.xml (EX-101.DEF) — 12KB
- mbrx-20250818_lab.xml (EX-101.LAB) — 15KB
- mbrx-20250818_pre.xml (EX-101.PRE) — 12KB
- mbrx20250818c_8k_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On August 18, 2024, the Company held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). As of June 20, 2025, the record date for the Annual Meeting, there were 14,127,494 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 6,041,112 shares were present in person or represented by proxy, which constituted a quorum. The holders of shares of our common stock are entitled to one vote for each share held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting. Each of these proposals is described in greater detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on July 8, 2025 (the "Proxy Statement"). Proposal 1. Election of Directors - The Company's stockholders elected Walter V. Klemp, Robert E. George, Michael D. Cannon, John Climaco, Elizabeth A. Cermak, and Joy Yan to serve until the next Annual Meeting of Stockholders, or until such person's successor is qualified and elected. Director Name Votes For Votes Withheld Broker Non-Votes Walter V. Klemp 1,033,770 345,745 4,661,597 Robert E. George 1,062,309 317,206 4,661,597 Michael D. Cannon 1,034,411 345,104 4,661,597 John Climaco 1,047,623 331,892 4,661,597 Elizabeth A. Cermak 1,029,972 349,543 4,661,597 Joy Yan 1,050,419 329,096 4,661,597 Proposal 2. Ratify Grant Thornton LLP as Independent Registered Public Accountant - The Company's stockholders ratified the appointment of Grant Thornton, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025, by the following vote: Votes For Votes Against Abstain Broker Non-Votes 5,320,203 697,886 23,023 N/A Proposal 3. Approve an Amendment to the Moleculin Biotech, Inc. 2024 Equity Incentive Plan to Inc